TSNA exposure: Levels of NNAL among Canadian tobacco users

Nicotine and Tobacco Research

Volumn 17, Issue 7, 2015, Pages 825-830

  Czoli, Christine D ^a   Hammond, David ^a  

^a UNIVERSITY OF WATERLOO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

4 (METHYLNITROSAMINO) 1 (3 PYRIDYL) 1 BUTANOL; COTININE; CREATININE; NITROSAMINE; 4-(METHYLNITROSAMINO)-1-(3-PYRIDYL)-1-BUTAN-1-OL; BIOLOGICAL MARKER; CARCINOGEN; PYRIDINE DERIVATIVE;

ADOLESCENT; ADULT; AGED; ARTICLE; CANADIAN; CHILD; CREATININE URINE LEVEL; FEMALE; HUMAN; MALE; PRIORITY JOURNAL; TOBACCO USE; URINE LEVEL; CANADA; CROSS-SECTIONAL STUDY; EPIDEMIOLOGY; MIDDLE AGED; SMOKING; URINE; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; BIOMARKERS; CANADA; CARCINOGENS; CHILD; COTININE; CROSS-SECTIONAL STUDIES; FEMALE; HUMANS; MALE; MIDDLE AGED; NITROSAMINES; PYRIDINES; SMOKING; TOBACCO USE; YOUNG ADULT;

EID: 84927778983     PISSN: 14622203     EISSN: 1469994X     Source Type: Journal    
DOI: 10.1093/ntr/ntu251     Document Type: Article

References (22)

1. Krueger H, Turner D, Krueger J, Ready AE. The economic benefits of risk factor reduction in Canada: tobacco smoking, excess weight and physical inactivity. Can J Public Health. 2014;105:e69-e78.
2. Reid JL, Hammond D, Burkhalter R, Rynard VL, Ahmed R. Tobacco Use in Canada: Patterns and Trends, 2013 Edition. Waterloo, Canada: Propel Centre for Population Health Impact, University of Waterloo; 2013. http://www.tobaccoreport.ca/. Accessed July 13, 2014.
3. International Agency for Research on Cancer (IARC). Tobacco smoke and involuntary smoking. IARC Monographs on the Evaluation of Carcinogenic Risks to Humans. Vol. 83. Lyon, France: IARC; 2004.
4. U.S. Department of Health and Human Services. How Tobacco Smoke Causes Disease. The Biology and Behavioral Basis for Smoking-Attributable Disease. A Report of the Surgeon General. 2010. http://www.cdc.gov/tobacco/data_statistics/sgr/2010/index.htm?s_cid=cs_1843. Accessed July 13, 2014.
5. Gray N, Boyle P. The case of the disappearing nitrosamines: a potentially global phenomenon. Tob Control. 2004;13:13-16.
6. Hecht SS. Human urinary carcinogen metabolites: biomarkers for investigating tobacco and cancer. Carcinogenesis. 2002;23:907-922.
7. Hammond D, O'Connor RJ. Constituents in tobacco and smoke emissions from Canadian cigarettes. Tob Control. 2008;17(suppl 1):i24-i31.
8. Rickert WS, Joza PJ, Sharifi M, Wu J, Lauterbach JH. Reductions in the tobacco specific nitrosamine (TSNA) content of tobaccos taken from commercial Canadian cigarettes and corresponding reductions in TSNA deliveries in mainstream smoke from such cigarettes. Regul Toxicol Pharmacol. 2008;51:306-310.
9. Hammond D, Fong GT, Cummings KM, Hyland A. Smoking topography, brand switching, and nicotine delivery: results from an in vivo study. Cancer Epidemiol Biomarkers Prev. 2005;14:1370-1375.
10. Jarvis MJ, Boreham R, Primatesta P, Feyerabend C, Bryant A. Nicotine yield from machine-smoked cigarettes and nicotine intakes in smokers: evidence from a representative population survey. J Natl Cancer Inst. 2001;93:134-138.
11. U.S. Department of Health and Human Services. Monograph 13. Risks Associated With Smoking Cigarettes With Low Machine-Measured Yields of Tar and Nicotine. 2001. http://cancercontrol.cancer.gov/brp/tcrb/monographs/13/. Accessed July 13, 2014.
12. Appleton S, Olegario RM, Lipowicz PJ. TSNA exposure from cigarette smoking: 18 years of urinary NNAL excretion data. Regul Toxicol Pharmacol. 2014;68:269-274.
13. Xia Y, Bernert JT, Jain RB, Ashley DL, Pirkle JL. Tobacco-specific nitrosamine 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol (NNAL) in smokers in the United States: NHANES 2007-2008. Biomarkers. 2011;16: 112-119.
14. Ashley DL, O'Connor RJ, Bernert JT, et al. Effect of differing levels of tobacco-specific nitrosamines in cigarette smoke on the levels of biomarkers in smokers. Cancer Epidemiol Biomarkers Prev. 2010;19:1389-1398.
15. Statistics Canada. Canadian Health Measures Survey (CHMS). 2011. http://www23.statcan.gc.ca/imdb/p2SV.pl?Function=getSurvey&SDDS=5071. Accessed July 13, 2014.
16. SRNT Subcommittee on Biochemical Verification. Biochemical verification of tobacco use and cessation. Nicotine Tob Res. 2002;4:149-159.
17. World Health Organization (WHO). Framework Convention on Tobacco Control. 2003. http://www.who.int/fctc/text_download/en/. Accessed July 13, 2014.
18. World Health Organization (WHO). The Scientific Basis of Tobacco Product Regulation. Second Report of a WHO Study Group. 2008. http://www.who.int/tobacco/global_interaction/tobreg/publications/tsr_951/en/. Accessed July 13, 2014.
19. Food and Drug Administration (FDA). Overview of the Family Smoking Prevention and Tobacco Control Act. 2013. http://www.fda.gov/downloads/TobaccoProducts/GuidanceComplianceRegulatoryInformation/UCM336940.pdf. Accessed July 13, 2014.
20. Church TR, Anderson KE, Caporaso NE, et al. A prospectively measured serum biomarker for a tobacco-specific carcinogen and lung cancer in smokers. Cancer Epidemiol Biomarkers Prev. 2009;18:260-266.
21. Yuan JM, Koh WP, Murphy SE, et al. Urinary levels of tobacco-specific nitrosamine metabolites in relation to lung cancer development in two prospective cohorts of cigarette smokers. Cancer Res. 2009;69:2990-2995.
22. King B, Borland R, Fowles J. Mainstream smoke emissions of Australian and Canadian cigarettes. Nicotine Tob Res. 2007;9:835-844.